학술논문

Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT
Document Type
article
Source
Prostate Cancer and Prostatic Diseases. 26(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Immunology
Radiation Oncology
Immunotherapy
Cancer
Prostate Cancer
Clinical Research
Urologic Diseases
Aging
6.5 Radiotherapy and other non-invasive therapies
Male
Humans
Prostatic Neoplasms
Radiosurgery
Prostate
CD8-Positive T-Lymphocytes
Cell Count
Urology & Nephrology
Clinical sciences
Oncology and carcinogenesis
Language
Abstract
BackgroundRadiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients.MethodsProstate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy.ResultsTwo weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.